wow - Charles Lieber, the retired Harvard University chemist convicted in 2021 for not disclosing his China ties, joined Tsinghua University as a chair professor

www.scmp.com/news/china/s...

Misunderstanding of drug labels can be dangerous for the patient and costly for the healthcare system.

I visited a social enterprise in Hong Kong trying to prevent that by promoting traffic sign-like icons:

www.bloomberg.com/news/newslet...

Ascentage Pharma, which scored an option deal and equity investment from Takeda earlier this year, is another step closer to a Nasdaq IPO after securing a listing notice from the China Securities Regulatory Commission.

The US-China biotech is developing targeted cancer therapies

ADC assets from WuXi Biologics revive a struggling US biotech:

Aadi Bioscience, which laid off the majority of its staff in August after disappointing results, "transforms" by licensing 3 ADCs from WuXi and Hangzhou DAC, selling its only commercial drug for $100M and raising another $100M in a PIPE

ICYMI: Lilly's Kisunla approved in China to treat early symptomatic Alzheimer's disease, facing off Biogen/Eisai's Leqembi

www.prnewswire.com/news-release...

Last night, China unveiled latest batch of 62 drugs added to volume-based procurement (VBP) program. The bulk purchase program, which focuses on off-patent drugs, is designed to push prices down

Notably, unlike in previous years, authorities didn't disclose the average price cut

Still slowly moving over. For new #biosky friends: I write about the growing role Asia, in particular China, plays on the global business of creating new medicines. I also track the evolving China biopharma market, among other things.

Here's a recent story:

www.bloomberg.com/news/article...

Merck partner Kelun Biotech says its TROP2 ADC — the most advanced program in their deal — is approved in China

sacituzumab tirumotecan (SKB264/MK-2870) is the first homegrown ADC to win China OK. Merck is running global Phase 3 trials

initial indication: 3rd line TNBC

China has pledged to encourage more research in gene and cell therapies at the country’s biotech hub in the eastern Chinese city of Suzhou, in the latest bid to bolster the country’s standing at the cutting edge of global drug research.

www.bloomberg.com/news/article...